Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering
the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including
maximal surgical resection, radiation therapy, and chemotherapy (typically temozolomide), have not led to
significant changes in the survival rates of GBM patients. However, emerging modalities, such as the use of tyrosine
kinase inhibitors, mTOR inhibitors, NF-κB modulators, nitrosoureas, and immunotherapeutic agents have shown
promising in improving GBM outcomes. In this context, we reviewed the current status of GBM treatment, the
efficacy of existing standard therapies in improving disease outcomes, and future therapeutic directions.